{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2020.05.29.20109199v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2020.05.29.20109199v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2020.05.29.20109199v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EABSTRACT\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E Effective therapies are needed to control the SARS-Cov-2 infection pandemic and reduce mortality associated with COVID-19. Several clinical studies have provided evidence for the antiviral effects of type I interferons (IFNs) in patients with respiratory coronaviruses. This study assessed the therapeutic efficacy of IFN-\u03b12b in patients infected with SARS-CoV-2 during the first month after the outbreak began in Cuba.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EMethod\u003C\/strong\u003E This multicenter prospective observational study was conducted in 16 hospitals in 8 Cuban provinces. Participants were patients with confirmed SARS-CoV-2 infection detected from throat swab specimens by real time RT-PCR who gave informed consent and had no contraindications for IFN treatment. Patients received therapy as per the Cuban COVID protocol, that included a combination of oral antivirals (lopinavir\/ritonavir and chloroquine) with intramuscular administration of IFN-\u03b12b (Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R, Center for Genetic Engineering and Biotechnology, Havana), 3 times per week, for 2 weeks. The primary endpoint was the proportion of patients discharged from hospital (without clinical and radiological symptoms and non-detectable virus by RT-PCR). The secondary endpoint was the case fatality rate (CFR), defined as the number of confirmed deaths divided by the number of confirmed cases.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003EResults\u003C\/strong\u003E From March 11\u003Csup\u003Eth\u003C\/sup\u003E to April 14\u003Csup\u003Eth\u003C\/sup\u003E, 814 patients were confirmed SARS-CoV-2 positive in Cuba, 761 (93.4%) were treated with Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R and 53 received the approved protocol without IFN treatment. The proportion of fully recovered patients was higher in the IFN-treated compared with non-IFN treated group (95.4% vs 26.1%, \u003Cem\u003Ep\u003C\/em\u003E\u0026lt;0.01). The CFR for all patients was 2.95%, and for those patients who received IFN-\u03b12b the CFR was reduce to 0.92. The estimated global CFR is 6.34% and 4.05% for the Americas reported by WHO and PAHO, respectively. In this study, 82 patients (10.1%) required intensive care and, of these, 42 (5.5%) were treated with IFN.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EConclusions\u003C\/strong\u003E This report provides preliminary evidence for the therapeutic effectiveness of IFN\u03b1-2b for COVID-19 and suggests that the use of Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R may contribute to complete recovery.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EINTRODUCTION\u003C\/h2\u003E\u003Cp id=\u0022p-19\u0022\u003EThe clinical spectrum of COVID-19 varies from asymptomatic infection to mild symptoms to severe acute respiratory illness and death\u003Csup\u003E\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E\u003C\/sup\u003E. There is an urgent need for antiviral drugs to effectively treat this disease.\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EDue to their antiviral properties and known mechanisms of action, type I interferons (IFN-\u03b1\/\u03b2) present as candidate broad spectrum antivirals for global virus outbreaks\u003Csup\u003E\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E\u003C\/sup\u003E. In a recent clinical study, evidence was provided that IFN-\u03b12b treatment accelerated viral clearance from the airways and reduced circulating levels of the inflammatory biomarkers IL-6 and CRP in COVID-19 cases\u003Csup\u003E\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EIn previous coronavirus epidemics in 2002 (SARS-CoV) and 2012 (MERS-CoV), evidence was provided that coronaviruses encode in their genome factors that specifically block an IFN response, including preventing the activation of MyD88 associated with IFN production and STAT1, associated with IFN signaling\u003Csup\u003E\u003Ca id=\u0022xref-ref-3-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E\u003C\/sup\u003E. Notably, for both outbreaks, evidence was provided for the antiviral effects of type I IFNs, suggesting that IFN treatment can override the inhibitory effects of coronaviruses\u003Csup\u003E\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EIn the absence of a vaccine, a number of candidate antivirals are currently under consideration around the globe. Remdesivir is considered the most promising \u003Csup\u003E\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E; it functions by inhibiting the activity of RNA-dependent RNA polymerases (RdRp). Case studies describing the use of remdesivir for COVID-19 have been reported\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E\u003C\/sup\u003E. Ongoing randomized, controlled clinical trials will evaluate the safety and antiviral efficacy of remdesivir in patients with mild to moderate or severe COVID-19 (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04292899\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022\u003ENCT04292899\u003C\/a\u003E,  \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04292730\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022\u003ENCT04292730\u003C\/a\u003E,  \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04257656\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022\u003ENCT04257656\u003C\/a\u003E,  \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04252664\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022\u003ENCT04252664\u003C\/a\u003E,  \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04280705\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022\u003ENCT04280705\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EFavipiravir, an anti-influenza medication that also is an RdRp inhibitor is under investigation for COVID-19, but to date, clinical data suggest limited efficacy\u003Csup\u003E\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E. The HIV protease inhibitor lopinavir\/ritonavir (LPV\/RTV) has seen disappointing outcomes in COVID-19 patients\u003Csup\u003E\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E\u003C\/sup\u003E, this despite evidence for LPV\/RTV plus ribavirin being effective \u003Cem\u003Ein vitro\u003C\/em\u003E against SARS-CoV\u003Csup\u003E\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EThe antiviral activities of chloroquine\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E and hydroxychloroquine\u003Csup\u003E\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/sup\u003E against SARS-Cov-2, prompted further evaluation in clinical studies, where early data suggest that they may contribute to inhibition of pneumonia exacerbation and shortening of disease course\u003Csup\u003E\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EGuidelines issued by the expert committee of the World Health Organization (WHO) identified IFN-\u03b12b as a potential antiviral for the treatment and prevention of COVID-19\u003Csup\u003E\u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E\u003C\/sup\u003E. Early on in the outbreak, the Chinese government recommended the use of IFN-\u03b1 for the treatment of COVID-19\u003Csup\u003E\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E\u003C\/sup\u003E. Several ongoing clinical studies evaluating IFN-\u03b12b for the treatment of COVID-19 are registered at clinicaltrials.gov\u003Csup\u003E\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-26\u0022\u003EHeberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R (human recombinant IFN-\u03b12b) produced by the Center for Genetic Engineering and Biotechnology, Havana, Cuba, has demonstrated antiviral efficacy and a proven safety profile over 34 years\u003Csup\u003E\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E\u003C\/sup\u003E. Herein, we report the first results of the use of Heberon\u00ae Alpha R as part of the Cuban protocol\u003Csup\u003E\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E\u003C\/sup\u003E for the management of COVID-19.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-6\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMATERIALS AND METHODS\u003C\/h2\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPatients and treatments\u003C\/h3\u003E\u003Cp id=\u0022p-27\u0022\u003EA multicenter, prospective, observational study was conducted, that included all patients in Cuba with confirmed SARS-CoV-2 infection during the first 33 days of the epidemic in the country, March 11 to April 14, 2020. Patients were recruited from 16 hospitals in 8 Cuban provinces. Individuals were considered COVID-19 positive based on virus detected by real time polymerase chain reaction (RT-PCR).\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003EPatients with confirmed SARS-CoV-2 infection, who gave informed consent and had no contraindications for IFN treatment described in the product information sheet, received therapy as approved in the Cuban COVID protocol. Namely, a combination of antivirals and intramuscular Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R (IFN-\u03b12b, liquid formulation) administration. Antivirals used were lopinavir\/ritonavir (Kaletra) (250 mg, one capsule b.i.d. (500 mg\/day) for 30 days and chloroquine 150 mg, one tablet twice a day (300 mg\/day) for 10 days. IFN treatment was administered by intramuscular injection 3 million IU 3 times per week, for 2 weeks. To treat pediatric cases, the three drugs were adjusted for age and weight or body surface (i.e. IFN: 100.000 IU\/Kg). Patients with contraindications or who did not consent to receive IFN were treated with the Cuban protocol lacking IFN, i.e. only lopinavir\/ritonavir and chloroquine. For those cases whose disease progressed to become severe and critical, requiring ICU support, treatment with Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R was stopped.\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EAddition of Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R to the Cuban protocol was approved by the Cuban National Regulatory Authority, CECMED, which maintained surveillance of the scientific evidence obtained. The protocol of this study was evaluated and approved by a centralized Research Ethics Committee, representing all hospital institutions enrolled in the diagnosis and treatment of patients. This clinical research is registered with the code RPCEC00000318 in the Cuban Public Registry of Clinical Trials\u003Csup\u003E\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EData presented are from patient medical records provided by the Cuban Ministry of Public Health, in accordance with the policies established for an investigation in a pandemic scenario.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPCR confirmation of SARS-CoV-2\u003C\/h3\u003E\u003Cp id=\u0022p-31\u0022\u003EA qualitative real time polymerase chain reaction (RT-PCR) for SARS-CoV-2 was performed. Throat swab specimens from the upper respiratory tract of patients were placed into collection tubes prefilled with 150 \u03bcL of virus preservation solution, and total RNA was extracted using commercial kits: LightMix\u00ae Modular Sarbecovirus E-gene (Roche), LightMix\u00ae Modular SARS-COV-2 (COVID19 RDRP-GENE) (Roche), LightMix\u00ae Modular EAV RNA Extraction Control (Roche), LightCycler Multiplex RNA Virus Master (Roche), QIAamp\u00ae Viral RNA MiniKit (250) (Quiagen). RT-PCR positivity was required prior to treatment onset, and PCR testing was performed every 72 hours thereafter. Samples were designated positive (+) or negative (-).\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003EHematological and biochemical profiles were assessed at admission and every 72 hours using routine clinical laboratory procedures.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EEndpoints\u003C\/h3\u003E\u003Cp id=\u0022p-33\u0022\u003EThe primary endpoint was the proportion of patients discharged from hospital (i.e. discharge criteria were the absence of clinical and radiological symptoms and non-detectable virus, as determined by 2 consecutive PCR(-)s at least 24 hours apart. The secondary endpoint was the case fatality rate, (CFR), defined as the number of confirmed deaths divided by the number of confirmed cases.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatistical analyses\u003C\/h3\u003E\u003Cp id=\u0022p-34\u0022\u003EDescriptive statistics were used to estimate the measures of central tendency and dispersion (media and extreme values) in demographic characteristics. The association between qualitative variables was analyzed using contingency tables. For the comparison of proportions the Fisher exact test calculator was used. The odds ratio (OR) was applied as a measure of association between treatments and outcomes. The non-parametric Mann-Whitney U test was used for comparing independents samples.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-11\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ERESULTS AND DISCUSSION\u003C\/h2\u003E\u003Cp id=\u0022p-35\u0022\u003EAll confirmed patients with COVID-19 in Cuba during the period March 11\u003Csup\u003Eth\u003C\/sup\u003E to April 14\u003Csup\u003Eth\u003C\/sup\u003E 2020 were included in this study. The Cuban protocol\u003Csup\u003E\u003Ca id=\u0022xref-ref-20-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E\u003C\/sup\u003E for clinical management of COVID-19 was initiated on March 11\u003Csup\u003Eth\u003C\/sup\u003E, 2020, concomitant with the diagnosis of the first three patients in the country. By April 14\u003Csup\u003Eth\u003C\/sup\u003E, according to the Cuban Ministry of Public Health\u003Csup\u003E\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E\u003C\/sup\u003E, 814 individuals had been confirmed positive for SARS-CoV-2 infection, 761 of them (93.4%) were treated with the established protocol including Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R and 53 (6.6%) received the Cuban protocol without IFN.\u003C\/p\u003E\u003Cp id=\u0022p-36\u0022\u003E\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E\u003C\/strong\u003E describes the demographics of all patients included in this study. The distribution conformed to findings around the globe. The average age of all cases was 44.3 years, with a non-significant difference between the sexes.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/221536\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/221536\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/221536\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EDemographics \u0026amp; clinical characteristics of patient cohort\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-37\u0022\u003EPatients who did not receive IFN were older (median 66.9 years vs 42.9 years) with a higher incidence of comorbidities (56.6% vs 3.2%), such as high blood pressure, ischemic heart disease and diabetes mellitus.\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003EData analyses were limited, because the study endpoint outcomes, namely hospital discharge (recovery) and CFR for a large number of the cases remained unknown at the time of study termination. On April 14\u003Csup\u003Eth\u003C\/sup\u003E, 639 patients remained hospitalized under protocol care (herein considered as patients with unknown outcome).\u003C\/p\u003E\u003Cp id=\u0022p-39\u0022\u003EFor individuals with known outcomes (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E\u003C\/strong\u003E), a higher proportion of patients who became PCR SARS-CoV-2 negative and resolved their disease, were IFN-treated, than not (95.4% vs 26.1%, \u003Cem\u003Ep\u003C\/em\u003E\u0026lt;0.01). According to the Odds Ratio estimation, an individual treated with Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R had a 58.7 times greater advantage to achieve recovery.\u003C\/p\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/221533\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/221533\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/221533\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EIFN treatment promotes recovery from COVID-19\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-40\u0022\u003EOn the cut-off date (April 14, 2020), the overall Cuban CFR was 2.95%\u003Csup\u003E\u003Ca id=\u0022xref-ref-22-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E\u003C\/sup\u003E. The CFR for patients treated with IFN-\u03b12b was 0.92 (\u003Cem\u003Ep\u003C\/em\u003E\u0026lt;0.01). These CFRs are lower than those reported on the same date by the WHO\u003Csup\u003E\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E\u003C\/sup\u003E: Global CFR=6.34% and PAHO\u003Csup\u003E\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E\u003C\/sup\u003E CFR=4.05% (for the region of the Americas).\u003C\/p\u003E\u003Cp id=\u0022p-41\u0022\u003ETo better address the influence of IFN treatment on CFR, we next considered the clinical status of patients in the context of severity of disease, using admission to ICU as a criterion for severe disease.\u003C\/p\u003E\u003Cp id=\u0022p-42\u0022\u003E82 patients (10.1% of all the COVID-19 cases) required intensive care, of which 42 had been treated with IFN. Notably, this is 5.5% of the total number of COVID-19 cases that had been treated with IFN. 67 (8.2% of all the COVID-19 cases) patients progressed to a serious or critical state of the disease, as characterized by a requirement for artificial ventilation and Acute Respiratory Distress Syndrome. 35 of these had not been treated with IFN-\u03b12b (representing 66.0% of COVID-19 cases that had not received IFN treatment). By contrast, 32 patients who progressed to serious or critical disease had received treatment with IFN-\u03b12b (representing 4.2% of the COVID-19 cases that had received IFN treatment). The data suggest that treatment with IFN limits progression to severe disease \u003Cem\u003E(p\u0026lt;0.05)\u003C\/em\u003E. IFN treatment was withdrawn for those patients who progressed to critical disease. Nevertheless, the effects of IFN treatment on subsequent CFR revealed that prior IFN treatment was associated with a 3.37 times greater likelihood of survival, since those critical patients not treated with IFN (48.6%) did not survive, compared to 21.9% of the IFN-treated patient who did survive (\u003Cem\u003Ep\u003C\/em\u003E\u0026lt;0.05).\u003C\/p\u003E\u003Cp id=\u0022p-43\u0022\u003EIn this study the median age was higher in those patients that did not receive IFN. Despite this, data analysis revealed that age was not a variable that negated the effects of IFN treatment.\u003C\/p\u003E\u003Cp id=\u0022p-44\u0022\u003ENotably, the CFR of COVID-19 by age was consistent with data from other countries that suggest that the elderly are at greater risk for severe disease and death\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E. In our study, 22 of the 24 (91.7%) fatalities, were older than 44.3 years and 19 (79.2%) were older than 55 years.\u003C\/p\u003E\u003Cp id=\u0022p-45\u0022\u003EThere were more deaths among males: 16 males compared with 8 females. Our data indicate that the estimated CFR in males with comorbidities is higher for individuals above the age of 45 years: 16.5 times greater likelihood of death.\u003C\/p\u003E\u003Cp id=\u0022p-46\u0022\u003EIrrespective of age, CFRs for those with comorbidities is much higher (87.5% vs 0.52%). In our study cohort, 7 (1.8%) of those under 45 years of age and 47 (11.4%) older had co-morbidities. Those individuals with comorbidities died: 21 (38.9%), compared to those with no co-morbidity 3 (0.39%). Elderly age and arterial hypertension represented the major risk predictors for death; in patients over 55 years, this increased from 4.9% to 38.9%.\u003C\/p\u003E\u003Cp id=\u0022p-47\u0022\u003EThe lower incidence of comorbidities in the IFN-treated patients may have contributed to their 4.34-fold greater survival advantage compared with those had not been treated with IFN (\u003Cstrong\u003E\u003Ca id=\u0022xref-table-wrap-1-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E\u003C\/strong\u003E). However, this advantage disappears in the subgroup of 28 patients with high blood pressure. High blood pressure was a comorbidity in 27 (32.9%) of the 82 patients who required intensive care. After adjusting for demographic characteristics, the IFN-related CFR was affected by comorbidity (\u003Cem\u003Ep\u003C\/em\u003E=1 \u00d7 10\u003Csup\u003E-4\u003C\/sup\u003E) and age (\u003Cem\u003Ep\u003C\/em\u003E=0.02) and remained significant regardless of sex (\u003Cem\u003Ep\u003C\/em\u003E=0.29).\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003EThe limitations of this open, non-randomized observational study include unbalanced demographics between treatment arms of unequal size. Nevertheless, the purpose of this study was to rapidly evaluate if inclusion of IFN-\u03b12b at the doses and therapeutic regimen employed, offered a therapeutic benefit to COVID-19 cases. Recent publications suggest that treatment with chloroquine\u003Csup\u003E\u003Ca id=\u0022xref-ref-16-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E\u003C\/sup\u003E or lopinavir\/ritonavir\u003Csup\u003E\u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E\u003C\/sup\u003E may offer little therapeutic benefit in COVID-19. With this information, we postulate that IFN treatment is likely the active antiviral in the regimen employed. Regardless of the identified limitations, therefore, our findings suggest that IFN-\u03b12b treatment may be effective for the treatment of COVID-19\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-12\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ECONCLUSION\u003C\/h2\u003E\u003Cp id=\u0022p-49\u0022\u003EThis report provides evidence of the effectiveness of IFN-\u03b12b as an antiviral treatment for COVID-19 and suggests that the use of Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R may contribute to recovery from COVID-19. These data extracted from clinical records of all patients in the first month of the epidemic, reveals that the use of Heberon\u003Csup\u003E\u00ae\u003C\/sup\u003E Alpha R improved both the rates of recovery and case fatalities.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-13\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-50\u0022\u003EHere I state the availability of all data referred to in the manuscript\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-14\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EContributors\u003C\/h2\u003E\u003Cp id=\u0022p-51\u0022\u003EDG, RV, BJR and DRE were responsible for patient care and treatment, RHB, RJC, OA, LLR and MN made clinical oversight and clinical data collection, PR led the working group, analyzed and conducted data analysis, data interpretation, literature searches and manuscript writing.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-15\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDeclaration of interests\u003C\/h2\u003E\u003Cp id=\u0022p-53\u0022\u003EThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgement\u003C\/h2\u003E\u003Cp id=\u0022p-52\u0022\u003EThe authors are grateful to Dr. Eleanor Fish from Toronto General Hospital Research Institute, University Health Network and Department of Immunology, University of Toronto, Toronto, ON, Canada, who reviewed the data and assisted with the interpretation and writing of the manuscript.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EREFERENCES\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.1\u0022 data-doi=\u002210.1016\/j.jaut.2020.102433\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERothan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EByrareddy\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESN\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EThe epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Autoimmun\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E May; \u003Cspan class=\u0022cit-vol\u0022\u003E109\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E102433\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/j.jaut.2020.102433\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BAutoimmun%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jaut.2020.102433%26rft_id%253Dinfo%253Apmid%252F32113704%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jaut.2020.102433\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32113704\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.2\u0022 data-doi=\u002210.3949\/ccjm.87a.ccc013\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMiller\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEnglund\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical presentation and course of COVID-19\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECleve Clin J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E May 5.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.3949\/ccjm.87a.ccc013\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DCleve%2BClin%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.3949%252Fccjm.87a.ccc013%26rft_id%253Dinfo%253Apmid%252F32371564%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToiY2Nqb20iO3M6NToicmVzaWQiO3M6ODoiODcvNy8zODQiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMC8wNi8wOS8yMDIwLjA1LjI5LjIwMTA5MTk5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.3\u0022 data-doi=\u002210.1016\/j.smim.2019.101300\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFish\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEN\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EGlobal virus outbreaks: interferons as 1st responders\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESemin Immunol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E43\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E101300\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSemin%2BImmunol%26rft.volume%253D43%26rft.spage%253D101300%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.smim.2019.101300%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.smim.2019.101300\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.4\u0022 data-doi=\u002210.3389\/fimmu.2020.01061\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EShannon\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWei\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EXS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EXu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETebbutt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESJ\u003C\/span\u003E\u003C\/span\u003E,. \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKollmann\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETR\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFish\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEN\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EInterferon-a2b treatment for COVID-19\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFrontiers Immunol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E6\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.3389\/fimmu.2020.01061\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DFrontiers%2BImmunol%26rft.volume%253D11%26rft.spage%253D1%26rft_id%253Dinfo%253Adoi%252F10.3389%252Ffimmu.2020.01061%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.3389\/fimmu.2020.01061\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.5\u0022 data-doi=\u002210.1001\/jama.290.24.3222\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELoutfy\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBlatt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESiminovitch\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EInterferon alfacon-1plus corticosteroids in severe acute respiratory syndrome\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E: \u003Cspan class=\u0022cit-vol\u0022\u003E290\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E3222\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E28\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft.stitle%253DJAMA%26rft.aulast%253DLoutfy%26rft.auinit1%253DM.%2BR.%26rft.volume%253D290%26rft.issue%253D24%26rft.spage%253D3222%26rft.epage%253D3228%26rft.atitle%253DInterferon%2BAlfacon-1%2BPlus%2BCorticosteroids%2Bin%2BSevere%2BAcute%2BRespiratory%2BSyndrome%253A%2BA%2BPreliminary%2BStudy%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.290.24.3222%26rft_id%253Dinfo%253Apmid%252F14693875%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jama.290.24.3222\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=14693875\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000187499300026\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.6\u0022 data-doi=\u002210.1099\/vir.0.061911-0\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHart\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDyall\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPostnikova\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EInterferon-\u00df and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Gen Virol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E95\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E571\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E77\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BGen%2BVirol%26rft_id%253Dinfo%253Adoi%252F10.1099%252Fvir.0.061911-0%26rft_id%253Dinfo%253Apmid%252F24323636%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1099\/vir.0.061911-0\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24323636\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJean\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES-S\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ETreatment options for COVID-19: The reality and challenges\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Microbiology, Immunology and Infection\u003C\/abbr\u003E, \u003Ca href=\u0022https:\/\/doi.org\/10.10167j.jmii.2020.03.034\u0022\u003Ehttps:\/\/doi.org\/10.10167j.jmii.2020.03.034\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.8\u0022 data-doi=\u002210.1056\/NEJMoa2001191\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHolshue\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EML\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeBolt\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELindquist\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al\u003C\/span\u003E; \u003Cspan class=\u0022cit-article-title\u0022\u003EWashington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E382\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E929\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E936\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1056\/NEJMoa2001191\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2001191%26rft_id%253Dinfo%253Apmid%252F32004427%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa2001191\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32004427\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.9\u0022 data-doi=\u002210.1101\/2020.03.09.20032896\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKujawski\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ESA\u003C\/span\u003E\u003C\/span\u003E,\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECollins\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EFirst 12 patients with coronavirus disease 2019 (COVID-19) in the United States\u003C\/span\u003E. medRxiv. Preprint posted March 9, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1101\/2020.03.09.20032896\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft_id%253Dinfo%253Adoi%252F10.1101%252F2020.03.09.20032896%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMC4wMy4wOS4yMDAzMjg5NnYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjAvMDYvMDkvMjAyMC4wNS4yOS4yMDEwOTE5OS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.10\u0022 data-doi=\u002210.1001\/jama.2020.6019\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESanders\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMonogue\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EML\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJodlowski\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ETZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECutrell\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJB\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E323\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E18\u003C\/span\u003E): \u003Cspan class=\u0022cit-fpage\u0022\u003E1824\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E1836\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1001\/jama.2020.6019\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2020.6019%26rft_id%253Dinfo%253Apmid%252F32282022%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jama.2020.6019\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32282022\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.11\u0022 data-doi=\u002210.1056\/NEJMoa2001282\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB\u003C\/span\u003E\u003C\/span\u003E,\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E,\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWen\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. Published online March 18, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1056\/NEJMoa2001282\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2001282%26rft_id%253Dinfo%253Apmid%252F32187464%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa2001282\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32187464\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.12\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECheng\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EVC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHung\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ERole of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EThorax\u003C\/abbr\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2004\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E59\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E252e6\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DThorax%26rft.volume%253D59%26rft.spage%253D252e6%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.13\u0022 data-doi=\u002210.1016\/j.ijantimicag.2020.105938\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDevaux\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERolain\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EColson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERaoult\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ENew insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19\u003C\/span\u003E? \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInt J Antimicrob Agents\u003C\/abbr\u003E. Published online March 11, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/j.ijantimicag.2020.105938\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInt%2BJ%2BAntimicrob%2BAgents%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ijantimicag.2020.105938%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.ijantimicag.2020.105938\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F09%2F2020.05.29.20109199.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.14\u0022 data-doi=\u002210.1016\/j.ijantimicag.2020.105932\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EColson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERolain\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELagier\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrouqui\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERaoult\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EChloroquine and hydroxychloroquine as available weapons to fight COVID-19\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInt J Antimicrob Agents\u003C\/abbr\u003E. Published online March 4, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/j.ijantimicag.2020.105932\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInt%2BJ%2BAntimicrob%2BAgents%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ijantimicag.2020.105932%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.ijantimicag.2020.105932\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGao\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E., \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETian\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBreakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETrends\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E; \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E: \u003Cspan class=\u0022cit-fpage\u0022\u003E72\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E73\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTrends%26rft.volume%253D14%26rft.spage%253D72%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.05.29.20109199v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWorld Health Organization\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003EWorld Health Organization\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/apps.who.int\/iris\/handle\/10665\/330893\u0022\u003Ehttps:\/\/apps.who.int\/iris\/handle\/10665\/330893\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17. in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.17\u0022 data-doi=\u002210.20944\/preprints202004.0207.v1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EQiu\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELiang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDabbous\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWang\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EToumi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EChinese Guidelines Related to Novel Coronavirus Pneumonia\u003C\/span\u003E. Preprints \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2020040207\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E (\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.20944\/preprints202004.0207.v1\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft_id%253Dinfo%253Adoi%252F10.20944%252Fpreprints202004.0207.v1%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.20944\/preprints202004.0207.v1\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.05.29.20109199v1.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBelhadi\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPeiffer-Smadja\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYazdanpanah\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMentr\u00e9\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELaou\u00e9nan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA brief review of antiviral drugs evaluated in registered clinical trials for COVID-19\u003C\/span\u003E. MedRxiv. preprint doi \u003Ca href=\u0022https:\/\/doi.org\/10.1101\/2020.03.18.20038190.2020.03.18.20038190\u0022\u003Ehttps:\/\/doi.org\/10.1101\/2020.03.18.20038190.2020.03.18.20038190\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19. in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENodarse-Cuni\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELopez-Saura\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECuban interferon alpha-2b. Thirty years as an effective and safe drug\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiotecnol Apl\u003C\/abbr\u003E, ene.-mar. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E, vol.\u003Cspan class=\u0022cit-vol\u0022\u003E34\u003C\/span\u003E, no.\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E, p.\u003Cspan class=\u0022cit-fpage\u0022\u003E1211\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E1217\u003C\/span\u003E. ISSN 1027-2852.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiotecnol%2BApl%26rft.volume%253D34%26rft.spage%253D1211%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EInfomed\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EPortal of the Cuban Health Network. (w.d.). Cuban Protocol against COVID 19. Ministry of Public Health\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/instituciones.sld.cu\/facultadfinlayalbarran\/protocolo-cuba-vs-covid-4-4-2020\u0022\u003Ehttps:\/\/instituciones.sld.cu\/facultadfinlayalbarran\/protocolo-cuba-vs-covid-4-4-2020\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ENational Coordinating Center for Clinical Trials\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ECuban Public Registry of Clinical Trials.. (w.d.)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMinistry of Public Health\u003C\/abbr\u003E. \u003Ca href=\u0022https:\/\/rpcec.sld.cu\/ensayos-promotor\/Ministerio-de-Salud-Publica-AM\u0022\u003Ehttps:\/\/rpcec.sld.cu\/ensayos-promotor\/Ministerio-de-Salud-Publica-AM\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.05.29.20109199v1.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ECuban Ministry of Public Health\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClosing part of the day April 14 at 12 midnight\u003C\/abbr\u003E, April 15. \u003Ca href=\u0022https:\/\/salud.msp.gob.cu\/?p=4814\u0022\u003Ehttps:\/\/salud.msp.gob.cu\/?p=4814\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-2020.05.29.20109199v1.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWorld Health Organization\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u003Cspan class=\u0022cit-source\u0022\u003ECoronavirus disease (COVID-2019) situation reports-85\u003C\/span\u003E, 14 April. \u003Cspan class=\u0022cit-publ-name\u0022\u003EWorld Health Organization\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\u0022\u003Ehttps:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-book\u0022 id=\u0022cit-2020.05.29.20109199v1.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EPan American Health Organization\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u003Cspan class=\u0022cit-source\u0022\u003ECumulative suspected and confirmed COVID-19 cases reported by countries and territories in the Americas\u003C\/span\u003E, as of 14 April 2020, 14 April. \u003Cspan class=\u0022cit-publ-name\u0022\u003EPan American Health Organization\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.paho.org\/en\/documents\/cumulative-suspected-and-confirmed-covid-19-cases-reported-countries-and-territories-19\u0022\u003Ehttps:\/\/www.paho.org\/en\/documents\/cumulative-suspected-and-confirmed-covid-19-cases-reported-countries-and-territories-19\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_H97bJNYldrxCr3hCb6fk0pHqZhxSyU-JJrTH50GZbsI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}